| アブストラクト | Reports suggested the potential occurrence of peripheral neuropathies (PN) in patients treated with BRAF (BRAFi) and/or MEK inhibitors (MEKi) for BRAF-activated tumours. We aimed to better characterize these PN. We queried the French pharmacovigilance database for all cases of PN attributed to BRAFi and/or MEKi. Fifteen patients were identified. Two main clinical PN phenotypes were seen. Six patients presented a length-dependent, axonal polyneuropathy: symptoms were mostly sensory and affecting the lower limbs; management and outcome were variable. Nine patients developed a demyelinating polyradiculoneuropathy: symptoms affected the four limbs and included hypoesthesia, weakness and ataxia; cranial nerves were involved in four cases; most patients received intravenous immunoglobulins or glucocorticoids, with variable outcome; one patient was rechallenged with a different BRAFi/MEKi combination with a rapid relapse in symptoms. In conclusion, patients under BRAFi/MEKi therapy may develop treatment-induced PN. Two main phenotypes can occur: a symmetric, axonal, length-dependent polyneuropathy and a demyelinating polyradiculoneuropathy. |
|---|
| 投稿者 | Picca, Alberto; Birzu, Cristina; Berzero, Giulia; Sanchez-Pena, Paola; Gaboriau, Louise; Vidil, Faustine; Lenglet, Timothee; Tafani, Camille; Ricard, Damien; Psimaras, Dimitri; Bihan, Kevin |
|---|
| 組織名 | Sorbonne Universite, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP,;Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Paris, France.;OncoNeuroTox Group, Center for Patients with Neurological Complications of;Oncologic Treatments, GH Pitie-Salpetriere et Hopital Percy, Paris, France.;Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.;Vita-Salute San Raffaele University, Milan, Italy.;Service de Pharmacologie medicale, Pole de Sante Publique, CHU de Bordeaux,;Bordeaux, France.;Centre Regional de Pharmacovigilance, Service de Pharmacologie Medicale, CHU de;Lille, Lille, France.;Agence National de Securite du Medicament et des Produits de Sante, Saint-Denis,;France.;Departement de Neurophysiologie Clinique, AP-HP, GH Pitie-Salpetriere, Paris,;Departement de Neurologie, Hopital d'instruction des Armees Percy, Service de;Sante des Armees, Paris, France.;Departement de Pharmacologie, AP-HP, GH Pitie-Salpetriere, Centre regional de;Pharmacovigilance, Paris, France. |
|---|
